INVESTOR DEADLINE: Corcept Therapeutics Incorporated (CORT) Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit – RGRD Law

Core Viewpoint - The article discusses a class action lawsuit against Corcept Therapeutics Incorporated, alleging violations of the Securities Exchange Act of 1934 related to the company's new drug application for relacorilant, which was not adequately supported by clinical evidence as claimed by the company [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated" and allows purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, to seek appointment as lead plaintiff by April 21, 2026 [1]. - The lawsuit alleges that Corcept misrepresented the status of the relacorilant New Drug Application (NDA), claiming it was supported by strong evidence and was nearing approval, while the FDA had raised concerns about the clinical evidence [3][4]. - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the relacorilant NDA, stating that additional evidence of effectiveness was required, leading to a stock price drop of over 50% [4]. Group 2: FDA Concerns and Implications - The FDA's CRL, published on January 30, 2026, detailed concerns regarding the adequacy of clinical studies submitted for relacorilant, indicating that the evidence was insufficient for the proposed indication [5]. - The FDA had previously communicated concerns about the clinical development program to Corcept during pre-submission meetings, warning of potential significant review issues if the application was submitted [5]. Group 3: Legal Representation and Firm Background - Robbins Geller Rudman & Dowd LLP is representing investors in the class action lawsuit and is recognized as a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].